Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction

Kiuchi, Shunsuke; Hisatake, Shinji; Kabuki, Takayuki; Oka, Takahiro; Dobashi, Shintaro; Fujii, Takeshiro; Ikeda, Takanori

doi:10.1080/10641963.2016.1267198

Cited by 10 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main characteristics of all included trials, including 12 940 patients with HFpEF are displayed in Table 1. Five publications evaluated the effectiveness of BBs, 15,16,19,20,24 while five articles evaluated the effectiveness of CCBs 17,18,21–23 . In all included investigations, the median follow‐up time ranged from 1 month to 42 months.…”

Section: Resultsmentioning

confidence: 99%

“…Five publications evaluated the effectiveness of BBs, 15,16,19,20,24 while five articles evaluated the effectiveness of CCBs. 17,18,[21][22][23] In all included investigations, the median follow-up time ranged from 1 month to 42 months.…”

Section: Discussionmentioning

confidence: 99%

“…A computerized data extraction form was developed in Microsoft Excel and utilized for the purpose of listing the fundamental information of the studies [15][16][17][18][19][20][21][22][23][24] selected for the meta-analysis. This included the first author's name, the year of publication, the intervention, the sample size in each group, the duration of followup, and the outcomes.…”

Section: Data Extractionmentioning

confidence: 99%

“…Figure1depicts the funnel plot, which T A B L E 1 Characteristics of included studies. mortality, Length of Hospital stay Kiuchi et al17…”

mentioning

confidence: 99%

See 3 more Smart Citations

Association between the beta‐blockers, calcium channel blockers, all‐cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta‐analysis of randomized controlled trials

Wu¹,

Linling³

et al. 2023

Clinical Cardiology

View full text Add to dashboard Cite

PurposeTo establish an association between beta‐blockers (BBs), calcium channel blockers (CCBs), all‐cause mortality, and hospitalization in patients with Heart failure with preserved Ejection Fraction (HFpEF).MethodsThe present meta‐analysis has been performed as per the guidelines of (PRISMA). An inclusive literature search was made without any limitations on language using the electronic databases Cochrane Library, EMBASE, and PubMed up to November 2022. The outcomes evaluated in this meta‐analysis involved all‐cause mortality and hospitalization due to heart failure. The number of patients with HFpEF and their positive outcomes was extracted and analyzed using RevMan software.ResultsIn total, 10 articles were included in the present meta‐analysis, with a pooled sample size of 12 940 HFpEF patients. In comparison with placebo, both BB and CCB substantially reduced the risk of all‐cause mortality and hospitalization. However, BB are more effective because they provide a significant reduction in all‐cause mortality (risk ratio (RR) = 0.60; 95% confidence interval [CI] = 0.43–0.83; p = .002] and hospitalization (RR = 0.54; 95% CI = 0.37–0.80; p = .002) as compared with CCB with a risk ratio of all‐cause mortality (RR = 0.77; 95% CI = 0.60–0.98; p = .03) and hospitalization (RR = 0.63; 95% CI = 0.44–0.90; p < .00001). A random‐effects model was used because of high heterogeneity between the studies (I2 > 70%).ConclusionsThe current meta‐analysis suggests that BBs were more beneficial than CCB in reducing all‐cause mortality and hospitalization duration in patients with HFpEF.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Data Extractionmentioning

confidence: 99%

“…Figure1depicts the funnel plot, which T A B L E 1 Characteristics of included studies. mortality, Length of Hospital stay Kiuchi et al17…”

mentioning

confidence: 99%

See 2 more Smart Citations

Association between the beta‐blockers, calcium channel blockers, all‐cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta‐analysis of randomized controlled trials

Wu¹,

Linling³

et al. 2023

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…By virtue of this ability, Azelnidipine inhibits the inflammatory mediators and has shown to be effective in treating atherosclerosis, caused by damage of endothelial cells by all inflammatory interleukins, cytokines, tumor necrosis factors and monocytes, etc. [6,7].…”

Section: Introductionmentioning

confidence: 99%

Bioequivalence Study of Azelnidipine 16 Mg Tablet to Evaluate Pharmacokinetic Profile of Single Dose in Healthy, Adult, Human Volunteers Under Fasting Condition

Das¹,

Halder

Bose³

et al. 2021

Int J App Pharm

View full text Add to dashboard Cite

Objective: The present study's objective is to conduct a comparative bioavailability study with a special emphasis on the test product's bioequivalence using a standard reference product as a comparator. Methods: Before initiating the bioequivalent study, the plasma sample analysis method was developed and validated by using LC-MS/MS method. The entire study was conducted as a single-dose crossover randomized bioequivalence study with open-label, two treatment, two-period, and two sequences on 24 healthy volunteers under fasting condition. With proper informed consent process the oral dose of the Reference product (R) or Test product (T) was administered on healthy volunteers at 0 h during each period of the study. After the drug's oral administration, a certain quantity of blood sample was collected, and the plasma sample was separated using a cold centrifuge. The plasma samples were analysed by using the validated LC-MS/MS method. The pharmacokinetic parameters, statistical data and ANOVA of the test and reference product were evaluated. Results: The Cmax, Auc0-t, AUC0-∞ and tmax of the test product were found to be 6.29 ng/ml, 117.0 ng. h/ml, 161.67 ng. h/ml and 3.33 h. respectively. And the Cmax, Auc0-t, AUC0-∞ and tmax of reference product were found 6.59 ng/ml, 123.21 ng. h./ml, 172.20 ng. h/ml and 3.38 h respectively. Relative bioavailability was found 94.96%. The overall results show that the 90% confidence intervals (Log-Transformed and Untransformed) for Cmax, AUC0-t and AUC0-∞ for Azelnidipine were within the acceptable limit of 80%-125%. Conclusion: The entire study's conclusion can be drawn as the test product was bioequivalent with the reference product's comparator.

show abstract

Cardiac sympathetic nerve activity trends after renal denervation in heart failure with preserved ejection fraction

Shiraki,

Mizuno,

Kishi

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

This case report describes the application of ultrasound renal denervation (uRDN) using the Paradise System in a patient with heart failure with preserved ejection fraction. Initially, the cardiac sympathetic nerve activity of the patient exhibited a late heart/mediastinum (H/M) ratio of 2.00 and a washout rate of 66.0% by cardiac iodine‐123 metaiodobenzylguanidine (123I‐MIBG) scintigraphy. Subsequently, the patient underwent transfemoral uRDN targeting the left, right upper, and right lower renal arteries. At the 6 month follow‐up, no significant change was observed in 123I‐MIBG findings; however, the estimated stressed blood volume (eSBV) decreased from 1722 to 1029 mL/70 kg. At 18 months, 123I‐MIBG findings improved, with the late H/M ratio reaching 2.76 and the washout rate decreasing to 43.1%. This case report highlights the potential of uRDN in reducing eSBV within 6 months and subsequently improving cardiac sympathetic nerve activity at the 18 month follow‐up.

show abstract

Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction

Abstract: In patients with HT and HFpEF, azelnidipine improved the severity of HF and cardiac sympathetic nerve activity compared with cilnidipine.

Cited by 10 publications

References 21 publications

Association between the beta‐blockers, calcium channel blockers, all‐cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta‐analysis of randomized controlled trials

Association between the beta‐blockers, calcium channel blockers, all‐cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta‐analysis of randomized controlled trials

Bioequivalence Study of Azelnidipine 16 Mg Tablet to Evaluate Pharmacokinetic Profile of Single Dose in Healthy, Adult, Human Volunteers Under Fasting Condition

Cardiac sympathetic nerve activity trends after renal denervation in heart failure with preserved ejection fraction

Contact Info

Product

Resources

About